Cohesion Technologies
This article was originally published in The Gray Sheet
Executive Summary
Private placement raises $4 mil. for Cohesion's NeuColl osteobiologics subsidiary to fund a pivotal clinical study of its NeuVisc osteoarthritis treatment and expand Collagraft synthetic bone graft substitute commercialization. The single injection NeuVisc treatment, if approved by FDA, would compete with currently available hyaluronic acid-based synovial fluid supplements that require multiple intra-articular knee injections. Also under development is NeuGraft, a second generation fully resorbable bone graft substitute and High Density Collagen for a variety of potential resorbable fixation applications. The financing reduces Cohesion's ownership position in NeuColl to "under 50%," Cohesion notes